Bayer HealthCare Enhances US Research Strategy with New Innovation Center
New US Innovation Center in San Francisco’s Mission Bay will focus on developing partnerships with academic research institutions and small life science firms
Bayer HealthCare’s pharmaceutical division will establish a U.S. Innovation Center in San Francisco, Calif. with the goal to expand its global research network and build its specialty pharmaceutical pipeline. The model introduces a newly formed “Science Hub” for innovation sourcing in the US creating collaborations with academic research scientists and small biotech firms to realize product development and commercialization of new therapies through partnerships with Bayer. The U.S. Innovation Center also will house Bayer scientists who drive the company’s strong Hematology research program focused on coagulation factors and the discovery of novel biologic drug candidates.
The U.S. Innovation Center’s dedicated team of scientists will tap into the wealth of breakthrough thinking from the educational institutions and start up biotech companies to build partnerships and collaborations ranging from the research bench to the clinic. Bayer research scientists working in targeted areas such as cardiology, oncology, women’s healthcare and diagnostic imaging, will rotate through this science hub to collaborate with the critical mass of innovative thinking that is clustered in the Bay Area and broader U.S. life sciences sector. Bayer’s U.S. Innovation Center will feature state-of-the-art labs opening at 455 Mission Bay South in the fourth quarter 2010.
* BETASERON® (Interferon beta-1b) Prescribing Information.
* Kogenate® FS Antihemophilic Factor (Recombinant) Prescribing Information.
"Through our newest innovation center, US academic research institutions and young biopharmaceutical firms will work closely with Bayer scientists and leverage our experience in bringing novel discoveries to market. Working together, we have the potential to create significant benefits for patients,” said Professor Andreas Busch, Head of Global Drug Discovery for Bayer’s pharmaceutical division.
